Edwards Lifesciences is determined to have the last word in its ongoing patent feud with Medtronic over the companies' transcatheter aortic valve replacement (TAVR) products. CEO Mike Mussallem wrote a letter to customers and partners on Wednesday, offering the company's take on the recent legal proceedings and reassuring patients that they would still have access to life-saving therapies.
Medtronic is striking back in its latest battle with competitor Edwards over patents for the companies' transcatheter aortic valve replacement products. The company filed an emergency motion in a U.S. Circuit Court of Appeals to prevent an injunction against its CoreValve system from going into effect.
Edwards Lifesciences scored a major victory against competitor Medtronic in an ongoing patent war over the companies' transcatheter aortic valve replacement products. A U.S. District Court issued a preliminary injunction against Medtronic's CoreValve system, limiting sales of the device in the U.S.
Thanks to an FDA ruling, a fleet of Medtronic pacemakers and defibrillators are now cleared for use in patients with less severe heart failure.
Medical device companies with renal denervation platforms are facing yet another obstacle, as U.S. and European heart doctors are calling for a decrease or halt in the use of the devices to treat high blood pressure.
Medtronic is headed to the European market with what it says is the first implantable defibrillator cleared for full-body MRI scans, following a widespread trend toward imaging-safe implants.
A combination of physical therapy and treatment with Medtronic's spinal-cord-stimulating devices helped three men with paraplegia move their extremities and briefly stand up on their own, The Wall Street Journal reports, regaining voluntary movement years after their injuries.
Medtronic is looking to bypass some middlemen in its Turkish operation, buying a controlling stake in one of its distributors and launching a joint venture as it works to expand its share of the growing medical device market.
It's a crowded market for transcatheter aortic devices, and Boston Scientific is trying to get a leg up on the competition. The company is celebrating positive study results for its transcatheter aortic valve replacement, touting data that it hopes will set it apart from its market rivals.
Edwards Lifesciences' Sapien XT beat out Medtronic's CoreValve in the first head-to-head comparison of the two firms' competing transcatheter aortic valve replacements (TAVR). This small trial won't be the last word, but it's seen as a weapon in Edwards' market arsenal versus its rival in a market estimated at $3 billion a year.